

Patient Name: FAGGART, JEFFREY
Patient ID: 1081EMR
DOB, Age, Sex: 4/19/1965 52 Male
Client: (1028) Lags Spine and Sportscare
Requested By: Latavia Esters (1619157831)
Medications: Gabapentin, Norco

Accession: 1709220037
Collect Date: 09/13/2017
Receive Date: 09/22/2017
Tested Date: 09/27/2017
Release Date: 09/27/2017

REPORT SUMMARY

UNEXPECTED: Inconsistent Results Based on Patient's Declared Medications

Specimen ID	1709220037
Collection Date	9/13/2017
NONE	

EXPECTED: Consistent Results of Declared Medications & Metabolites

Specimen ID	1709220037
Collection Date	9/13/2017
Gabapentin	>2000
Hydrocodone	1058.1
Hydromorphone	71.1
Norhydrocodone	680.4

SPECIMEN VALIDITY RESULTS

Urine - Creatinine (mg/dL)	212	Abnormal	80-200
Urine - Oxidants (ug/mL)	0	Normal	0-200
Urine - PH Level	6.0	Normal	4.7-7.8
Urine - Specific Gravity Level	1.031	Normal	1.003-1.035

REPORT DETAILS

Test Name	Result (ng/ml)	Positive/Negative	Cutoff	Outcome
Amphetamine				
Amphetamine		Negative	<20	Consistent
Methylphenidate		Negative	<50	Consistent
Norpseudoephedrine		Negative	<10	Consistent
Ritalinic Acid		Negative	<50	Consistent
Benzodiazepines				
7-Aminoclonazepam		Negative	<4	Consistent
alpha-hydroxyalprazolam		Negative	<5	Consistent
Alprazolam		Negative	<4	Consistent
Clonazepam		Negative	<10	Consistent
Diazepam		Negative	<5	Consistent

Patient Name: FAGGART, JEFFREY
Patient ID: 1081EMR
DOB, Age, Sex: 4/19/1965 52 Male
Client: (1028) Lags Spine and Sportscare
Requested By: Latavia Esters (1619157831)
Medications: Gabapentin, Norco

Accession: 1709220037
Collect Date: 09/13/2017
Receive Date: 09/22/2017
Tested Date: 09/27/2017
Release Date: 09/27/2017

REPORT DETAILS

Test Name	Result (ng/ml)	Positive/Negative	Cutoff	Outcome
Flurazepam		Negative	<0.5	Consistent
Lorazepam		Negative	<10	Consistent
Meprobamate		Negative	<50	Consistent
Nordiazepam		Negative	<5	Consistent
Oxazepam		Negative	<5	Consistent
Temazepam		Negative	<20	Consistent
Neuromodulatory				
Carisoprodol		Negative	<20	Consistent
Gabapentin	>2000	Positive	<50	Consistent
Opiates and Semisynthetic Opioids				
Codeine		Negative	<50	Consistent
Hydrocodone	1058.1	Positive	<50	Consistent
Hydromorphone	71.1	Positive	<50	Consistent
Consistent because Hydromorphone is a metabolite of Norco				
Morphine		Negative	<50	Consistent
Norhydrocodone	680.4	Positive	<10	Consistent
Consistent because Norhydrocodone is a metabolite of Norco				
Noroxycodone		Negative	<10	Consistent
Oxycodone		Negative	<10	Consistent
Oxymorphone		Negative	<25	Consistent
Synthetic Opioids				
Buprenorphine Glucuronide		Negative	<10	Consistent
Buprenorphine		Negative	<10	Consistent
EDDP Percholate: Methadone Metabolite		Negative	<25	Consistent
Fentanyl		Negative	<2	Consistent
Meperidine		Negative	<10	Consistent
Methadone		Negative	<25	Consistent
Naloxone		Negative	<10	Consistent
Naltrexone		Negative	<20	Consistent
Norbuprenorphine		Negative	<30	Consistent
Normeperidine		Negative	<10	Consistent
Norbuprenorphine Glucuronide		Negative	<4	Consistent
Norfentanyl oxalate		Negative	<5	Consistent
Propoxyphene		Negative	<62.5	Consistent
Tapentadol		Negative	<20	Consistent
Tramadol HCL		Negative	<20	Consistent
Substances of Abuse				
6-MAM: Heroin Metabolite		Negative	<10	Consistent
Benzoylcegonine: Metabolite of Cocaine		Negative	<50	Consistent

Patient Name: FAGGART, JEFFREY
Patient ID: 1081EMR
DOB, Age, Sex: 4/19/1965 52 Male
Client: (1028) Lags Spine and Sportscare
Requested By: Latavia Esters (1619157831)
Medications: Gabapentin, Norco

Accession: 1709220037
Collect Date: 09/13/2017
Receive Date: 09/22/2017
Tested Date: 09/27/2017
Release Date: 09/27/2017

REPORT DETAILS

Test Name	Result (ng/ml)	Positive/Negative	Cutoff	Outcome
ETHYL GLUCURONIDE (EIA)		Negative	<500	Consistent
JWH-018 pentanoic		Negative	<5	Consistent
JWH-073 Butanoic		Negative	<5	Consistent
JWH-073 hydroxybutyl		Negative	<5	Consistent
Methylenedioxyamphetamine (MDA)		Negative	<100	Consistent
Methylenedioxyethylamphetamine (MDEA)		Negative	<100	Consistent
Methylenedioxymethamphetamine (MDMA)		Negative	<100	Consistent
Mephedrone		Negative	<10	Consistent
Methamphetamine		Negative	<100	Consistent
PCP (Phencyclidine) (EIA)		Negative	<25	Consistent
THC-COOH Glucuronide		Negative	<20	Consistent
11 Carboxy THC		Negative	<10	Consistent
Validity Tests EIA				
Urine - Creatinine (mg/dL)	212	Abnormal	80-200	
Urine - Oxidants (ug/mL)	0	Normal	0-200	
Urine - PH Level	6.0	Normal	4.7-7.8	
Urine - Specific Gravity Level	1.031	Normal	1.003-1.035	

*** Comments: Specimens received more than 3 days post collection may be compromised and not reflect actual concentration. This may limit detection of low levels. This test is not approved by the FDA for the treatment, diagnosis, or prevention, of any medical condition. It is performed for information and is intended for educational and research purposes only. Only a physician familiar with a Patient() 's individual medical history can make medical judgments and give that patient specific medical advice. results are not intended to be a substitute for consultation with a licensed health care provider.

Those analytes' test results, reported as detected by LC/MS, have not been approved by the FDA. The performance characteristics of the assays have been determined by National Labs in accordance with Clinical Laboratory Improvement Act of 1988 (CLIA '88) guidelines.

False positive and false negative test results do occur. A licensed health care provider must provide any interpretation or recommendation for treatment based upon test results. The results are not for use as evidence in civil or criminal cases. Specimens are not obtained under the guidelines required for secure collection and, therefore, cannot be used for employment purposes. The results are based upon the method used for testing and the sensitivity of that method. A negative result indicates that the drugs tested for were not detected at the sensitivity level used. Positive results may be possible with the same or subsequent specimens if testing is performed using a greater degree of sensitivity. Other factors that may affect the results include the type of drug; the amount, duration and time of last drug use; the body type and weight of the individual being testing; and, in the case of urine drug screens, the concentration, acidity, or alkalinity of the urine.